Combined effects of alcohol and hepatitis C: A secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence

Addictive Behaviors

Volumn 35, Issue 2, 2010, Pages 123-128

  Plebani, Jennifer G ^a   Tirado, Carlos F ^d   Pettinati, Helen M ^a   Kampman, Kyle M ^a   Volpicelli, Joseph R ^a   Oslin, David W ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Mental Illness Research   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alcohol dependence; CDT (carbohydrate deficient transferrin); GGT (gamma glutamyl transpeptidase); Hepatitis C; Risk assessment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DEFICIENT TRANSFERRIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CUTOFF VALUE; DRINKING BEHAVIOR; DRUG ABUSE; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PSYCHOSOCIAL CARE; VIRUS TRANSMISSION;

ADULT; ALANINE TRANSAMINASE; ALCOHOLISM; ASPARTATE AMINOTRANSFERASES; COCAINE-RELATED DISORDERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RISK FACTORS; RISK-TAKING; TRANSFERRIN;

EID: 70350755584     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2009.09.012     Document Type: Article

References (39)

1. Allen J.P., and Litten R.Z. The role of laboratory tests in alcoholism treatment. Journal of Substance Abuse Treatment 20 1 (2001) 81-85
2. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine 341 8 (1999) 556-562
3. Anand B.S., Currie S., Dieperink E., Bini E.J., Shen H., Ho S.B., Wright T., and VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 130 6 (2006) 1607-1616
4. Anton R.F. New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol, Clinical & Experimental Research 20 7 Suppl (1996) 3A-9A
5. Anton R.F., Lieber C., and Tabakoff B. Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use, results from a multisite study. Clinical & Experimental Research 26 8 (2002) 1215-1222
6. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of Hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine 144 10 (2006) 705-714
7. Avins A.L., Woods W.J., Lindan C.P., et al. HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. Journal of the American Medical Association 271 7 (1994) 515-518
8. Bell H., Tallaksen C., Sjåheim T., et al. Serum carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with chronic liver diseases. Alcoholism, Clinical & Experimental Research 17 2 (1993) 246-252
9. Bhattacharya R., and Shuhart M.C. Hepatitis C and alcohol, interactions, outcomes, and implications. Journal of Clinical Gastroenterology 36 3 (2003) 242-252
10. Boscarino J.A., Avins A.L., Woods W.J., et al. Alcohol-related risk factors associated with HIV infection among patients entering alcoholism treatment, implications for prevention. Journal of Studies on Alcohol 56 6 (1995) 642-653
11. Caldwell S.H., Halliday J.W., Fletcher L.M., et al. Carbohydrate-deficient transferrin in alcoholics with liver disease. Journal of Gastroenterology & Hepatology 10 2 (1995) 174-178
12. Carithers Jr. R.L., Marquardt A., and Gretch D.R. Diagnostic testing for hepatitis C. Seminars in Liver Disease 20 2 (2000) 159-171
13. Centers for Disease Control and Prevention. Recommendations for prevention and control of Hepatitis C Virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly 47 (1998) 1-54
14. Conigrave K.M., Saunders J.B., and Whitfield J.B. Diagnostic tests for alcohol consumption. Alcohol & Alcoholism 30 1 (1995) 13-26
15. DiMartini A., Day N., Lane T., et al. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcoholism, Clinical & Experimental Research 25 12 (2001) 1729-1733
16. Haley R.W., and Fischer R.P. The tattooing paradox, are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection?. Archives of Internal Medicine 163 9 (2003) 1095-1098
17. Kranzler H.R., and Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment, a meta-analysis. Alcohol, Clinical & Experimental Research 25 9 (2001) 1335-1341
18. Li T.K. Quantifying the risk for alcohol-use and alcohol-attributable health disorders: Present findings and future research needs. Journal of Gastroenterology and Hepatology 23 Suppl 1 (2008) S2-8
19. Limdi J.K., and Hyde G.M. Evaluation of abnormal liver function tests. Postgraduate Medical Journal 79 932 (2003) 307-312
20. Malow R.M., Devieux J.G., Jennings T., et al. Substance-abusing adolescents at varying levels of HIV risk, psychosocial characteristics, drug use, and sexual behavior. Journal of Substance Abuse 13 1-2 (2001) 103-117
21. McLellan A.T., Kushner H., Metzger D., et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9 3 (1992) 199-213
22. McLellan A.T., Luborsky L., Cacciola J., et al. New data from the Addiction Severity Index. Reliability and validity in three centers. Journal of Nervous and Mental Disease 173 7 (1985) 412-423
23. McLellan A.T., Luborsky L., Woody G.E., et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. Journal of Nervous and Mental Disease 168 1 (1980) 26-33
24. Metzger D.S., Woody G.E., McLellan A.T., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment, an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes 6 9 (1993) 1049-1056
25. Noguchi O., Yamaoka K., Ikeda T., et al. Clinicopathological analysis of alcoholic liver disease complicating chronic type C hepatitis. Liver 11 4 (1991) 225-230
26. Oslin D.W., Lynch K.G., Pettinati H.M., Kampman K.M., Gariti P., et al. A placebo controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcoholism, Clinical and Experimental Research 32 7 (2008) 1-10
27. Perret R., Froehlich F., Lavanchy D., et al. Is carbohydrate-deficient transferrin a specific marker for alcohol abuse? A study in patients with chronic viral hepatitis. Alcoholism, Clinical & Experimental Research 21 7 (1997) 1337-1342
28. Pettinati H.M., Kampman K.M., Lynch K.G., Suh J.J., Dackis C.A., Oslin D.W., and O'Brien C.P. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. Journal of Substance abuse Treatment 34 4 (2008) 378-390
29. Rosman A.S., and Lieber C.S. An overview of current and emerging markers of alcoholism. In: Litten R.Z., and Allen J.P. (Eds). Measuring Alcohol Consumption (1992), Humina Press, Totawa, NJ 99-134
30. Scouller K., Conigrave K.M., Macaskill P., et al. Should we use carbohydrate-deficient transferrin instead of gamma-glutamyltransferase for detecting problem drinkers? A systematic review and meta-analysis. Clinical Chemistry 46 12 (2000) 1894-18902
31. Silva I.S., Ferraz M.L., Perez R.M., et al. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. Journal of Gastroenterology & Hepatology 19 3 (2004) 314-318
32. Sobell L.C., and Sobell M.B. Timeline follow-back, a technique for assessing self-reported alcohol consumption. In: Litten R.Z., and Allen J.P. (Eds). Measuring Alcohol Consumption (1992), Humana Press Inc, Totowa, NJ 41-65
33. Sobell L.C., Sobell M.B., Leo G.I., et al. Reliability of a timeline method, assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. British Journal of Addiction 83 4 (1988) 393-402
34. Sorvajarvi K., Blake J.E., Israel Y., et al. Sensitivity and specificity of carbohydrate-deficient transferrin as a marker of alcohol abuse are significantly influenced by alterations in serum transferrin, comparison of two methods. Alcohol, Clinical & Experimental Research 20 3 (1996) 449-454
35. Stauber R.E., Stepan V., Trauner M., et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol & Alcoholism 30 2 (1995) 171-176
36. Stein M.D., Hanna L., Natarajan R., et al. Alcohol use patterns predict high-risk HIV behaviors among active injection drug users. Journal of Substance Abuse Treatment 18 4 (2000) 359-363
37. Stibler H., and Hultcrantz R. Carbohydrate-deficient transferrin in serum in patients with liver diseases. Clinical & Experimental Research 11 5 (1987) 468-473
38. Volpicelli J.R., Alterman A.I., Hayashida M., et al. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49 11 (1992) 876-880
39. Zakhari S., and Li T.K. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatology 46 6 (2007) 2032-2039